The Tumour Marker Group

Trine Bjøro
Group leader

Immunoassay techniques have revolutionized the determination of clinically relevant proteins and peptides. The Tumour Marker Group at MBK is one of the few hospital laboratories that still develops, validates and introduces novel “in house” assays into the clinic. We have more than 25 years of experience in the production of monoclonal antibodies (mAbs) for use in the construction of these specialized assays. Many of our mAbs have been licensed and are used in the manufacture of commercial assay kits that are in worldwide use. The challenges related to immunometric assays, particularly the problems caused by heterophilic antibodies or human anti-mouse antibodies have been thoroughly studied by the group and we have undertaken extensive studies on the incidence and prevention of interference in immunometric assays. In recent years we have also been highly involved in developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. By monitoring serum concentrations of these effective and expensive drugs, and identifying patients who produce neutralizing antibodies, clinicians may optimize the treatment for each individual patient.

Research projects

  • Developing immunoassays for human epidermal growth factor receptors 2, 3 and 4 and evaluating these receptors as tumour markers for HER2 positive breast cancer.
  • Developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases. A collaboration study with the Department of Pharmacology and clinicians at Rikshospitalet and Diakonhjemmet.
  • Late effects after testicular cancer; thyroid and kidney function, in collaboration with National Advisory Unit on Late Effects after Cancer Treatment.
  • Establishing reference intervals for human chorionicgonadotropin (hCG). 
  • Two dimensional chromatography combined with mass spectrometry is used to identify and quantitative tumour markers in collaboration with Dep. of Pharmaceutical Chemistry, UiO.
  • Part of the collaboration study “Hallmarks in lung cancer”; validating different markers for potential development of assays clinically useful in daily practice.

Contact information
Group leader professor Trine Bjøro, Department of Medical Biochemistry Oslo University Hospital, Radiumhospitalet Tel: +47 22935906 E-mail: